Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
Open Access
- 30 April 2019
- journal article
- research article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (2) , 218-226
Abstract
The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis. Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day). The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group. Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype.Keywords
This publication has 27 references indexed in Scilit:
- Evidence-based clinical practice guidelines for inflammatory bowel diseaseJournal of Gastroenterology, 2018
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementJournal of Crohn's and Colitis, 2017
- Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysisJournal of Crohn's and Colitis, 2015
- Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitisInflammatory Bowel Diseases, 2012
- The pattern and outcome of acute severe colitisJournal of Crohn's and Colitis, 2010
- Inflammatory bowel disease: cause and immunobiologyThe Lancet, 2007
- Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-RegressionClinical Gastroenterology and Hepatology, 2007
- A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitisGut, 2006
- Tacrolimus: a new immunosuppressive agentAmerican Journal of Health-System Pharmacy, 1995
- The mechanism of action of cyclosporin A and FK506Immunology Today, 1992